Evaluation of Prolact-Plus Human Milk Fortifier
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00486590|
Recruitment Status : Completed
First Posted : June 14, 2007
Last Update Posted : March 3, 2008
Prolacta Bioscience has developed the first purely human fortifier, Prolact-Plus, that can provide a source of many of the required nutrients for premature, newborn infants, particularly protein and calories. This product is made from donor human milk from which the skim (non-lipid portion) has been separated and then concentrated. A certain amount of the lipid content has been added back to achieve higher caloric content within a small delivery volume. The product is then pasteurized and filled in small quantities in order to allow for the addition of mother's own milk (or, possibly, milk from another donor). The goal of the preparation is to achieve an increase of approximately 4 cal/oz of mother's milk and to provide a protein level (when mixed with average pre-term milk) of about 3.5-3.8 g/100 Kcal of feed.
The data on Prolact-Plus will be obtained prospectively from infants who will receive human milk fortified in this fashion. The data on standard,bovine (cow)-fortified milk will be obtained retrospectively from medical records at the participating institutions. While this design is not necessarily optimal in this setting, it is an efficient and quick approach to evaluating the acute clinical effect of Prolact-Plus. It is anticipated that further studies will be conducted that will examine longer-term accounts and possibly do this in a controlled, randomized environment.
The goal of this study is to evaluate the short-term effect of Prolact-Plus fortified human milk when compared with bovine-based fortification of human milk on parameters such as growth and short-term development, infectious complications and incidence of feeding intolerance in a cohort design. Statistically, the study will attempt to evaluate a null hypothesis of equivalent results with respect to these parameters between the two types of fortifiers as compared with a two-sided alternative (difference between the groups).
In addition, data will be collected on overall survival and length of stay in the NICU. These data will be collected for descriptive purposes, although an attempt will be made to compare the findings with those obtained from the bovine-based fortifier.
|Condition or disease||Intervention/treatment|
|Infant, Very Low Birth Weight||Procedure: Prolact-Plus Human Milk Fortifier|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||105 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||The Evaluation of Prolact-Plus, Human Milk Fortifier (Human, Pasteurized) for Pre-Term Infants Receiving Human Milk|
|Study Start Date :||August 2006|
|Primary Completion Date :||August 2007|
|Study Completion Date :||August 2007|
- Feeding intolerance [ Time Frame: 30 days ]
- Necrotizing enterocolitis [ Time Frame: 30 days ]
- Length of stay in NICU and hospital [ Time Frame: Indeterminate ]
- Growth parameters, e.g. weight, head circumference, and length [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00486590
|United States, Florida|
|Shands Children's Hospital|
|Gainesville, Florida, United States, 32610-0296|
|Joe DiMaggio Children's Hospital|
|Hollywood, Florida, United States, 33021|
|Miami Children's Hospital|
|Miami, Florida, United States, 33155|
|United States, Indiana|
|Memorial Hospital of South Bend|
|South Bend, Indiana, United States, 46601|
|Study Director:||Martin L Lee, PhD||Prolacta Bioscience|